News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

curasan AG (DX:CUR): Bioactive Bone Regeneration Material Approved for Sale in Europe



10/21/2010 1:18:42 PM

Kleinostheim, Germany, 21st October 2010 – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8) has received European approval for its new granular bone regeneration material Ceracell®.

Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative biomaterials, customized to the needs of the users, both consistently and persistently. The launch of Ceracell® in the dental market is planned to coincide with the world’s largest international dental exhibition in Cologne (IDS) at the end of March next year, and it will be launched approximately three months later in the orthopaedic market.”

Ceracell® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration. Ceracell® is especially suitable when the body’s own healing potency needs to be reinforced by substances for bone growth such as PRP, BMP, bone marrow or stem cells.

Background information about curasan AG: Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.

Press Contact: curasan AG Andrea Weidner Tel. +49 (0)6027 40 900-51 Fax +49 (0)6027 40 900-39 andrea.weidner@curasan.de www.curasan.de

fr financial relations gmbh Jörn Gleisner Tel. +49 (0)69 95 90 83 20 Fax +49 (0)69 95 90 83 99 j.gleisner@finanical-relations.de


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES